Breaking News Instant updates and real-time market news.

2022-01-13 08:02:36 ALV Autoliv $105.52 / -1.77 (-1.65%) , APTV Aptiv $159.81 / +0.12 (+0.08%) … 08:02 01/13/22 01/13 08:02 01/13/22 08:02	Deutsche Bank sees 2022 guidance misses from these auto companies Deutsche Bank analyst Emmanuel Rosner sees potential for "notable 2022 guidance misses" from Autoliv (ALV), Aptiv (APTV) and Visteon (VC), followed by American Axle (AXL), Lear (LEA) and Dana (DAN). Further, Adient (ADNT) is potentially a "miss and cut" candidate, Rosner tells investors in a research note previewing the Q4 earnings and 2022 outlooks for the autos and auto technology industries. On the other hand, Rosner anticipates 2022 outlooks from General Motors (GM) and Ford (F) to be "solidly in-line or above modest Street expectations." This reflects "unusual concurrent positive industry conditions of volume recovery and robust pricing, offsetting cost inflation," the analyst writes. While not providing direct guidance, he also expects a positive update from Tesla (TSLA) on its growth and margin potential in 2022 and on the cadence of its new products and technology. ALV Autoliv $105.52 / -1.77 (-1.65%) APTV Aptiv $159.81 / +0.12 (+0.08%) VC Visteon $116.64 / +0.6 (+0.52%) AXL American Axle $9.64 / -0.07 (-0.72%) LEA Lear $185.58 / -1.19 (-0.64%) DAN Dana $24.13 / -0.19 (-0.78%) ADNT Adient $48.50 / -0.925 (-1.87%) GM General Motors $61.00 / -0.46 (-0.75%) F Ford $24.47 / +0.125 (+0.51%)	13 Jan 13 Jan 22 Jan

2022-01-13 08:02:36

ALV

Autoliv

$105.52 / -1.77 (-1.65%)

, APTV

Aptiv

$159.81 / +0.12 (+0.08%)

… 08:02

01/13/22

01/13

08:02

01/13/22

08:02

Deutsche Bank sees 2022 guidance misses from these auto companies

Deutsche Bank analyst Emmanuel Rosner sees potential for "notable 2022 guidance misses" from Autoliv (ALV), Aptiv (APTV) and Visteon (VC), followed by American Axle (AXL), Lear (LEA) and Dana (DAN). Further, Adient (ADNT) is potentially a "miss and cut" candidate, Rosner tells investors in a research note previewing the Q4 earnings and 2022 outlooks for the autos and auto technology industries. On the other hand, Rosner anticipates 2022 outlooks from General Motors (GM) and Ford (F) to be "solidly in-line or above modest Street expectations." This reflects "unusual concurrent positive industry conditions of volume recovery and robust pricing, offsetting cost inflation," the analyst writes. While not providing direct guidance, he also expects a positive update from Tesla (TSLA) on its growth and margin potential in 2022 and on the cadence of its new products and technology.

ALV

Autoliv

$105.52 / -1.77 (-1.65%)

APTV

Aptiv

$159.81 / +0.12 (+0.08%)

Visteon

$116.64 / +0.6 (+0.52%)

AXL

American Axle

$9.64 / -0.07 (-0.72%)

LEA

Lear

$185.58 / -1.19 (-0.64%)

DAN

Dana

$24.13 / -0.19 (-0.78%)

ADNT

Adient

$48.50 / -0.925 (-1.87%)

General Motors

$61.00 / -0.46 (-0.75%)

Ford

$24.47 / +0.125 (+0.51%)

13
Jan
13
Jan
22
Jan

OTHER BREAKING NEWS FROM THE FLY

Downgrade	Axon downgraded to Equal Weight from Overweight at Morgan Stanley » 06:42 05/23/22 05/23 06:42 05/23/22 06:42 AXON Axon $99.50 / +1 (+1.02%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events AXON Axon $99.50 / +1 (+1.02%) 05/19/22 Axon, Fusus partner to provide real-time community policing solutions 05/04/22 Axon names Jim Zito as interim CFO, succeeding Jawad Ahsan 04/18/22 Axon signs five-year contract with Columbus Division of Police 04/06/22 Axon acquires virtual reality training studio 'Foundry 45,' terms not disclosed AXON Axon $99.50 / +1 (+1.02%) 05/16/22 Baird Baird downgrades three cloud stocks on focus shift to cash flows 05/12/22 Northland Axon price target lowered to $130 from $180 at Northland 05/11/22 Baird Axon price target lowered to $125 from $145 at Baird 05/09/22 Credit Suisse Credit Suisse starts Axon at Outperform with $169 price target AXON Axon $99.50 / +1 (+1.02%) 05/10/22 Axon raises FY22 revenue view to $1.05B-$1.1B from $1.04B, consensus $1.05B 05/10/22 Axon reports Q1 adjusted EPS 45c, consensus 30c 05/04/22 Axon raises FY22 revenue view to $1.05B-$1.1B from $1.04B 02/24/22 Axon sees FY22 revenue $1.04B, consensus $1.01B AXON Axon $99.50 / +1 (+1.02%) 05/10/22 Fly Intel: After-Hours Movers 06/22/22 Axon
Initiation	Roivant Sciences initiated with an Outperform at SVB Leerink » 06:42 05/23/22 05/23 06:42 05/23/22 06:42 ROIV Roivant Sciences $3.72 / +0.075 (+2.06%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ROIV Roivant Sciences $3.72 / +0.075 (+2.06%) 05/16/22 Aruvant announces oral presentation on ARU-1801 05/02/22 Roivant Sciences announces collaborations in targeted protein degradation 05/02/22 Roivant Sciences appoints Srini Ramanathan as CDO 04/20/22 VantAI forms research collaboration with Boehringer Ingelheim ROIV Roivant Sciences $3.72 / +0.075 (+2.06%) 04/29/22 Cantor Fitzgerald Roivant Sciences initiated with an Overweight at Cantor Fitzgerald 12/15/21 Goldman Sachs Roivant Sciences initiated with a Buy at Goldman Sachs 12/02/21 H.C. Wainwright H.C. Wainwright says Arbutus patent win may mean 'considerable gain' for Roivant 11/08/21 H.C. Wainwright Roivant Sciences initiated with a Buy at H.C. Wainwright ROIV Roivant Sciences $3.72 / +0.075 (+2.06%) 02/14/22 Roivant Sciences reports Q4 EPS (41c), consensus (25c) ROIV Roivant Sciences $3.72 / +0.075 (+2.06%) 04/29/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/14/22 Fly Intel: Pre-market Movers 12/22/21 Fly Intel: After-Hours Movers ROIV Roivant Sciences $3.72 / +0.075 (+2.06%) 01/11/22 Nine new option listings on January 11th
Conference/Events	United Fire Group management to meet with Piper Sandler » 06:42 05/23/22 05/23 06:42 05/23/22 06:42 UFCS United Fire Group $29.42 / -1.13 (-3.70%) Meetings to be held in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events UFCS United Fire Group $29.42 / -1.13 (-3.70%) 05/18/22 United Fire Group increases quarterly dividend 6.7% to 16c per share 03/22/22 United Fire Group appoints Eric Martin CFO 02/22/22 United Fire Group CEO Randy Ramlo to retire 02/10/22 United Fire Group general counsel Neal Scharmer to retire UFCS United Fire Group $29.42 / -1.13 (-3.70%) 03/21/22 Piper Sandler United Fire Group price target raised to $37 from $30 at Piper Sandler 12/01/21 Piper Sandler United Fire Group upgraded to Overweight from Neutral at Piper Sandler 07/09/21 Piper Sandler United Fire Group price target lowered to $28 from $35 at Piper Sandler 06/28/21 Sidoti United Fire Group upgraded to Buy from Neutral at Sidoti UFCS United Fire Group $29.42 / -1.13 (-3.70%) 05/05/22 United Fire Group reports Q1 adjusted EPS $1.13, consensus 84c 02/15/22 United Fire Group reports Q4 adjusted EPS $1.69, consensus 41c 05/24/22 United Fire Group 05/25/22 United Fire Group 05/26/22 United Fire Group
Upgrade	Zebra Technologies upgraded to Equal Weight from Underweight at Morgan Stanley » 06:41 05/23/22 05/23 06:41 05/23/22 06:41 ZBRA Zebra Technologies $325.57 / +0.995 (+0.31%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options ZBRA Zebra Technologies $325.57 / +0.995 (+0.31%) 05/17/22 Zebra Technologies announces additional $1B share repurchase program 03/15/22 Zebra to acquire machine vision company Matrox Imaging for $875M 12/22/21 Optoro receives strategic investment led by Zebra Technologies 12/14/21 Zebra Technologies director Modruson sells 2,000 class A shares ZBRA Zebra Technologies $325.57 / +0.995 (+0.31%) 05/04/22 Needham Zebra Technologies price target lowered to $500 from $535 at Needham 05/04/22 Baird Zebra Technologies price target lowered to $440 from $550 at Baird 04/12/22 Morgan Stanley Morgan Stanley cuts Telecom & Networking Equipment industry view to Cautious 04/12/22 Morgan Stanley Zebra Technologies price target lowered to $400 from $470 at Morgan Stanley ZBRA Zebra Technologies $325.57 / +0.995 (+0.31%) 05/03/22 Zebra Technologies sees FY22 revenue growth of 3%-7%, consensus $5.95B 05/03/22 Zebra Technologies sees Q2 adjusted EPS $4.05 -$4.35, consensus $4.52 05/03/22 Zebra Technologies reports Q1 adjusted EPS $4.01, consensus $3.87 02/10/22 Zebra Technologies sees FY22 revenue growth of 3%-7%, consensus $5.92B ZBRA Zebra Technologies $325.57 / +0.995 (+0.31%) 04/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 00:00 Today 50th Annual Global Technology, Media & Communications Conference 09/12/22 Zebra Technologies - ZBRA ZBRA Zebra Technologies $325.57 / +0.995 (+0.31%) 04/04/22 Early notable gainers among liquid option names on April 4th
Initiation	Alteryx initiated with an Outperform at FBN Securities » 06:41 05/23/22 05/23 06:41 05/23/22 06:41 AYX Alteryx $55.68 / +0.16 (+0.29%) FBN Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options AYX Alteryx $55.68 / +0.16 (+0.29%) 04/05/22 Alteryx names Lucas Moody as Chief Information Security Officer 03/25/22 Alteryx announces strategic investment in Vertis 02/16/22 Alteryx rises 12.4% 02/16/22 Alteryx rises 8.7% AYX Alteryx $55.68 / +0.16 (+0.29%) 05/04/22 Loop Capital Alteryx price target raised to $67 from $60 at Loop Capital 05/04/22 Cowen Alteryx price target raised to $90 from $75 at Cowen 05/04/22 Citi Alteryx price target raised to $95 from $86 at Citi 04/01/22 Needham Alteryx price target raised to $86 from $66 at Needham AYX Alteryx $55.68 / +0.16 (+0.29%) 05/03/22 Alteryx sees FY22 non-GAAP EPS (56c)-(46c), consensus (64c) 05/03/22 Alteryx sees Q2 non-GAAP EPS (61c)-(58c), consensus (29c) 05/03/22 Alteryx reports Q1 non-GAAP EPS (40c), consensus (59c) 02/15/22 Alteryx sees FY22 adjusted EPS (68c)-(58c), consensus (8c) AYX Alteryx $55.68 / +0.16 (+0.29%) 02/16/22 What You Missed On Wall Street On Wednesday 02/16/22 What You Missed On Wall Street This Morning 02/15/22 Fly Intel: After-Hours Movers 02/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 00:00 Today 50th Annual Global Technology, Media & Communications Conference 06/01/22 50th Annual Technology, Media & Telecom Conference 06/07/22 Global Technology Conference 2022 05/25/22 Alteryx, Inc. AYX Alteryx $55.68 / +0.16 (+0.29%) 02/15/22 Alteryx options imply 14.2% move in share price post-earnings

Recommendations	April delinquency trends promising for Affirm, says Mizuho » 06:41 05/23/22 05/23 06:41 05/23/22 06:41 AFRM Affirm / + Mizuho analyst Dan Dolev… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AFRM Affirm / + 05/12/22 Affirm CEO: Our underlying business is performing very well 05/12/22 Affirm jumps 22% to $21.97 after Q3 results beat, FY22 guidance raised 05/12/22 Affirm extends multi-year partnership with Shopify in U.S. 05/04/22 Affirm to be first BNPL partner fully integrated to Carat from Fiserv AFRM Affirm / + 05/17/22 Mizuho Affirm price target lowered to $50 from $79 at Mizuho 05/16/22 Barclays Affirm price target lowered to $35 from $65 at Barclays 05/13/22 RBC Capital Affirm price target lowered to $48 from $58 at RBC Capital 05/13/22 Morgan Stanley Affirm results reassuring, investors likely still cautious, says Morgan Stanley AFRM Affirm / + 05/12/22 Affirm raises FY22 revenue view to $1.33B-$1.34B from at least $1.31B 05/12/22 Affirm sees Q4 revenue $345M-$355M, consensus $351.88M 05/12/22 Affirm reports Q3 EPS (19c), consensus (54c) 05/12/22 Notable companies reporting after market close AFRM Affirm / + 05/19/22 Klarna looks to raise up to $1B at lower valuation, WSJ reports 03/14/22 Affirm halts bond sale because of market volatility, Bloomberg reports 12/16/21 CFPB to seek buy now, pay later information from Affirm, others, Bloomberg says AFRM Affirm / + 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 05/13/22 Fly Intel: Pre-market Movers 05/12/22 Fly Intel: After-Hours Movers 00:00 Today 50th Annual Global Technology, Media & Communications Conference AFRM Affirm / + 05/13/22 Notable open interest changes for May 13th 05/12/22 Affirm Holdings options imply 29.7% move in share price post-earnings 04/25/22 Affirm Holdings call volume above normal and directionally bullish 04/22/22 Affirm Holdings call volume above normal and directionally bullish
Downgrade	Frontdoor downgraded to Hold from Buy at Truist » 06:41 05/23/22 05/23 06:41 05/23/22 06:41 FTDR Frontdoor $26.45 / +0.245 (+0.94%) Truist analyst Youssef… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings FTDR Frontdoor $26.45 / +0.245 (+0.94%) 05/20/22 Frontdoor CEO Rexford Tibbens to step down, chairman William Cobb to succeed FTDR Frontdoor $26.45 / +0.245 (+0.94%) 05/06/22 Truist Frontdoor price target lowered to $32 from $50 at Truist 05/06/22 Raymond James Frontdoor price target lowered to $31 from $40 at Raymond James 05/06/22 Oppenheimer Frontdoor price target lowered to $34 from $41 at Oppenheimer 01/06/22 Goldman Sachs Frontdoor assumed with a Neutral at Goldman Sachs FTDR Frontdoor $26.45 / +0.245 (+0.94%) 05/05/22 Frontdoor cuts FY22 revenue view $1.66B-$1.69B from $1.7B-$1.73B 05/05/22 Frontdoor sees Q2 revenue $475M-$485M, consensus $489.16M 05/05/22 Frontdoor reports Q1 adjusted EPS 4c, consensus 9c 02/24/22 Frontdoor sees FY22 revenue $1.70B-$1.73B, consensus $1.72B
Conference/Events	Timken management to meet with Loop Capital » 06:40 05/23/22 05/23 06:40 05/23/22 06:40 TKR Timken $57.88 / -0.735 (-1.25%) Meetings to be held in CA… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events TKR Timken $57.88 / -0.735 (-1.25%) 05/02/22 Timken reports Q1 adjusted EPS $1.61, consensus $1.16 04/29/22 Timken to acquire Spinea, terms undisclosed 02/15/22 Timken wins contract as provider of high-precision drives for solar power plant TKR Timken $57.88 / -0.735 (-1.25%) 05/03/22 KeyBanc Timken price target lowered to $75 from $84 at KeyBanc 04/13/22 Oppenheimer Timken initiated with an Outperform at Oppenheimer 02/15/22 Evercore ISI Timken upgraded to Outperform at Evercore ISI on relative valuation 02/15/22 Evercore ISI Oshkosh downgraded to In Line at Evercore ISI on relative valuation TKR Timken $57.88 / -0.735 (-1.25%) 05/02/22 Timken backs FY22 adjusted EPS $5.00-$5.40, consensus $5.23 02/03/22 Timken sees FY22 adjusted EPS $5.00-$5.40, consensus $5.71 02/03/22 Timken reports Q4 adjusted EPS 78c, consensus 91c 05/24/22 Timken 05/25/22 Timken
Upgrade	TreeHouse upgraded to Buy from Hold at Truist » 06:40 05/23/22 05/23 06:40 05/23/22 06:40 THS TreeHouse / + Truist analyst Bill… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events THS TreeHouse / + 05/16/22 Jana Partners exits Macy's, cuts LabCorp in Q1 05/09/22 TreeHouse rises 17.0% 04/12/22 TreeHouse appoints Scott Ostfeld of JANA Partners to board 03/14/22 TreeHouse provides update on strategic review of alternatives THS TreeHouse / + 03/22/22 Truist TreeHouse price target lowered to $35 from $40 at Truist THS TreeHouse / + 05/09/22 TreeHouse sees 2022 net sales growth of at least 11% y-o-y, consensus $4.75B 05/09/22 TreeHouse reports Q1 adjusted EPS (15c), consensus (52c) 03/14/22 TreeHouse backs FY22 revenue view up 11%, consensus $4.76B 02/14/22 TreeHouse sees FY22 revenue up 11%, consensus $4.43B THS TreeHouse / + 02/14/22 What You Missed On Wall Street On Monday 02/14/22 What You Missed On Wall Street This Morning 05/26/22 TreeHouse Foods, Inc.
Initiation	Upwork initiated with a Sector Perform at RBC Capital » 06:40 05/23/22 05/23 06:40 05/23/22 06:40 UPWK Upwork $18.32 / +0.24 (+1.33%) , MSFT Microsoft $252.57 / -0.44 (-0.17%) RBC Capital analyst Brad… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options UPWK MSFT UPWK Upwork $18.32 / +0.24 (+1.33%) 03/07/22 Upwork says a number of staff in Russia/Belarus region have already moved 03/07/22 Upwork CEO says suspending business in Russia 'a very difficult decision' 03/07/22 Upwork announces suspension of business in Russia, Belarus 01/06/22 Upwork announces Melissa Waters joins as chief marketing officer MSFT Microsoft $252.57 / -0.44 (-0.17%) 05/19/22 CD Projekt says next-gen 'Witcher 3' version to release in 4Q22 05/19/22 National Research Corporation appoints Parul Bhandari to board 05/19/22 Itron expands collaboration with Microsoft on cloud solutions for energy 05/18/22 American Airlines to use Microsoft Azure as its preferred cloud platform UPWK MSFT UPWK Upwork $18.32 / +0.24 (+1.33%) 05/17/22 Piper Sandler 'Interesting time' to be looking at Upwork story, says Piper Sandler 05/16/22 Stifel Upwork downgraded to Hold from Buy at Stifel 04/28/22 Needham Upwork price target lowered to $33 from $42 at Needham 04/28/22 Canaccord Upwork price target lowered to $36 from $40 at Canaccord MSFT Microsoft $252.57 / -0.44 (-0.17%) 05/19/22 RBC Capital Microsoft investor meetings indicate no change to macro/demand, says RBC Capital 05/13/22 Tigress Financial Microsoft pullback 'major buying opportunity,' says Tigress Financial 05/06/22 Benchmark Playstudios could still be target as industry consolidates, says Benchmark 04/29/22 OTR Global Okta view downgraded to Negative from Mixed at OTR Global UPWK MSFT UPWK Upwork $18.32 / +0.24 (+1.33%) 04/27/22 Upwork sees FY22 revenue $590M-$610M, consensus $599.52M 04/27/22 Upwork sees Q2 EPS (10c)-(6c), consensus (8c) 04/27/22 Upwork reports Q1 EPS (19c), consensus (14c) 03/07/22 Upwork withdraws Q1, 2022 guidance due to uncertainties amid Russian invasion MSFT Microsoft $252.57 / -0.44 (-0.17%) 04/26/22 Microsoft sees Q4 productivity and business processes revenue $16.65B-$16.9B 04/26/22 Microsoft reports Q3 EPS $2.22 consensus $2.18 04/26/22 Notable companies reporting after market close 01/25/22 Microsoft reports Q2 EPS $2.48, consensus $2.31 MSFT MSFT Microsoft $252.57 / -0.44 (-0.17%) 06:34 Today Electronic Arts reportedly looking to sell or merge, Kotaku reports 05/19/22 Microsoft president says Activision Blizzard deal proceeding quickly, VGC says 05/19/22 Xbox Series S outsold PlayStation 5 in Japan last week, Famitsu reports 05/18/22 Parent sues Blizzard over non-refundable 'Hearthstone' cards, Polygon reports UPWK MSFT UPWK Upwork $18.32 / +0.24 (+1.33%) 04/27/22 Fly Intel: After-Hours Movers 03/07/22 What You Missed On Wall Street On Monday 03/07/22 What You Missed On Wall Street This Morning 02/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations MSFT Microsoft $252.57 / -0.44 (-0.17%) 05/19/22 What You Missed On Wall Street On Thursday 05/17/22 What You Missed This Week in Video Games 05/12/22 What You Missed On Wall Street This Morning 05/10/22 What You Missed This Week in Video Games 00:00 Today 50th Annual Global Technology, Media & Communications Conference 06/14/22 Microsoft - MSFT 06/02/22 Upwork Inc. 06/06/22 Microsoft UPWK MSFT UPWK Upwork $18.32 / +0.24 (+1.33%) 02/10/22 Upwork options imply 12.7% move in share price post-earnings MSFT Microsoft $252.57 / -0.44 (-0.17%) 05/02/22 Microsoft put buyer realizes 57% same-day gains 04/27/22 Early notable gainers among liquid option names on April 27th 04/27/22 Notable open interest changes for April 27th 04/26/22 Microsoft call buyer realizes 19% same-day gains

Initiation	Radius Health initiated with a Market Perform at SVB Leerink » 06:40 05/23/22 05/23 06:40 05/23/22 06:40 RDUS Radius Health $6.25 / +0.41 (+7.03%) , AMGN Amgen $247.42 / +2.48 (+1.01%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options RDUS AMGN RDUS Radius Health $6.25 / +0.41 (+7.03%) 05/20/22 Radius Health appoints Jennifer Jarrett, Susan Vissers Lisa to board 05/20/22 Radius Health, Menarini announce data from EMERALD trial published 05/19/22 Radius Health announces publication of elacestrant clinical trial data 03/16/22 Radius Health appoints Conley as CFO, Clarke as General Counsel AMGN Amgen $247.42 / +2.48 (+1.01%) 05/16/22 Crispr Therapeutics appoints Morrow as CMO 05/04/22 BeiGene granted conditional approval of Blincyto by China NMPA 04/27/22 Amgen receives notice of deficiency from IRS for 2013-2015 period 04/27/22 Amgen's reports safety and efficacy results of Repatha Phase 3 studies RDUS AMGN RDUS Radius Health $6.25 / +0.41 (+7.03%) 12/23/21 Stifel New Radius' Tymlos label offers slight expansion potential, says Stifel 12/10/21 Morgan Stanley Radius Health downgraded to Underweight from Equal Weight at Morgan Stanley 12/09/21 Goldman Sachs Radius Health downgraded to Neutral from Buy at Goldman Sachs 12/09/21 H.C. Wainwright Radius Health price target lowered to $10 from $23 at H.C. Wainwright AMGN Amgen $247.42 / +2.48 (+1.01%) 06:20 Today SVB Leerink Amgen initiated with a Market Perform at SVB Leerink 05/10/22 Mizuho Amgen price target raised to $208 from $202 at Mizuho 05/05/22 Stifel ASCO sets up as 'downside-biased' for Mirati investors, says Stifel 04/28/22 BMO Capital Amgen price target lowered to $243 from $263 at BMO Capital RDUS AMGN RDUS Radius Health $6.25 / +0.41 (+7.03%) 05/05/22 Radius Health sees 2022 TYMLOS net revenue $232M 05/05/22 Radius Health reports Q1 EPS (39c), consensus (21c) 02/24/22 Radius Health reports Q4 adjusted EPS (5c), consensus (18c) 02/24/22 Radius Health sees 2022 Tymlos revenue of $232M AMGN Amgen $247.42 / +2.48 (+1.01%) 04/27/22 Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.63 04/27/22 Amgen reports Q1 adjusted EPS $4.25, consensus $4.10 04/27/22 Notable companies reporting after market close 02/08/22 Amgen sees FY22 revenue $25.4B-$26.5B, consensus $27B AMGN AMGN Amgen $247.42 / +2.48 (+1.01%) 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports 12/14/21 Moderna, Amgen among biotech companies pulling out of JPM conference, STAT says RDUS AMGN RDUS Radius Health $6.25 / +0.41 (+7.03%) 05/19/22 Fly Intel: After-Hours Movers 12/08/21 Wall Street in Fives - Must Read Lists for Wednesday 12/08/21 Wall Street in Fives - Must Read Lists at Midday AMGN Amgen $247.42 / +2.48 (+1.01%) 04/28/22 What You Missed On Wall Street On Thursday 04/27/22 Fly Intel: After-Hours Movers 02/08/22 Wall Street in Fives - Must Read Lists for Tuesday 02/08/22 Wall Street in Fives - Must Read Lists at Midday 06/03/22 2022 ASCO Annual Meeting 06/21/22 Amgen RDUS AMGN RDUS Radius Health $6.25 / +0.41 (+7.03%) 01/07/22 Unusually active option classes on open January 7th AMGN Amgen $247.42 / +2.48 (+1.01%) 02/08/22 Early notable gainers among liquid option names on February 8th 01/03/22 Amgen call volume above normal and directionally bullish
Hot Stocks	American Vanguard issues stockholder letter in support of director nominees » 06:38 05/23/22 05/23 06:38 05/23/22 06:38 AVD American Vanguard $22.31 / -0.52 (-2.28%) American Vanguard sent a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Events AVD American Vanguard $22.31 / -0.52 (-2.28%) 05/19/22 Glass Lewis urges American Vanguard investors to vote for Cruiser nominees 05/19/22 Cruiser Capital urges American Vanguard shareholders to vote for nominees 05/13/22 Cruiser Capital urges American Vanguard shareholders to vote for nominees 05/11/22 Cruiser Capital urges American Vanguard shareholders to vote for nominees 06/01/22 American Vanguard Corp
Initiation	Pfizer initiated with a Market Perform at SVB Leerink » 06:38 05/23/22 05/23 06:38 05/23/22 06:38 PFE Pfizer $52.46 / +1.805 (+3.56%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE Pfizer $52.46 / +1.805 (+3.56%) 05/17/22 Pfizer, BioNTech receive FDA emergency use authorization for child booster 05/17/22 FDA expands eligibility for Pfizer-BioNTech booster to kids 5-11 years old 05/16/22 Mirati Therapeutics appoints Laurie Stelzer as CFO 05/13/22 Pfizer EVP Carapezzi sells 32,908 common shares PFE Pfizer $52.46 / +1.805 (+3.56%) 05/11/22 H.C. Wainwright Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright 05/11/22 Wedbush Global Blood Therapeutics added to Best Ideas List at Wedbush 05/05/22 Stifel Stifel keeps Buy rating on Arvinas, lowers price target to $82 05/04/22 Wells Fargo Pfizer price target lowered to $55 from $60 at Wells Fargo PFE Pfizer $52.46 / +1.805 (+3.56%) 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open 05/02/22 Notable companies reporting before tomorrow's open PFE Pfizer $52.46 / +1.805 (+3.56%) 05/19/22 CDC panel backs booster dose for Pfizer COVID vaccine for kids aged 5-11 05/16/22 Pfizer, BioNTech Covid booster for kids 5-11 expected to be authorized, NYT says 05/04/22 FDA says no data support second course of Pfizer's Paxlovid, Bloomberg says 04/26/22 Biden administration to make Covid pills more widely available, WSJ reports PFE Pfizer $52.46 / +1.805 (+3.56%) 05/10/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street This Morning 05/10/22 Fly Intel: Pre-market Movers 05/03/22 What You Missed On Wall Street On Tuesday 06/02/22 38th Annual Strategic Decisions Conference 06/03/22 2022 ASCO Annual Meeting 08/06/22 Extended PDUFA Date for MYFEMBREE 05/26/22 Pfizer PFE Pfizer $52.46 / +1.805 (+3.56%) 05/20/22 Early notable gainers among liquid option names on May 20th 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 04/07/22 Pfizer call volume above normal and directionally bullish
Hot Stocks	Ocugen: FDA removes clinical hold on Phase 2/3 clinical trial for COVAXIN » 06:37 05/23/22 05/23 06:37 05/23/22 06:37 OCGN Ocugen $2.23 / -0.01 (-0.45%) Ocugen announced that the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options OCGN Ocugen $2.23 / -0.01 (-0.45%) 04/25/22 Ocugen announces positive DSMB recommendation for OCU400-101 clinical trial 04/18/22 Ocugen to commercialize COVAXIN in Mexico 04/12/22 Ocugen announces clinical hold on Phase 2/3 study of COVAXIN 04/01/22 Ocugen doses first patient in Phase 1/2 trial for OCU400 OCGN Ocugen $2.23 / -0.01 (-0.45%) 05/08/22 Chardan Chardan keeps Neutral on Ocugen, lowers price target to $3.50 04/18/22 Roth Capital Roth views Ocugen getting rights in Mexico as 'great news' 03/29/22 Chardan Ocugen price target lowered to $4 from $4.50 at Chardan 03/04/22 Roth Capital Roth says EUA denial takes accelerated Covaxin paths in U.S. off table in 2022 OCGN Ocugen $2.23 / -0.01 (-0.45%) 05/06/22 Ocugen reports Q1 EPS (9c), consensus 0c 02/25/22 Ocugen reports Q4 EPS (7c), consensus (6c) 23 Feb OCGN Ocugen $2.23 / -0.01 (-0.45%) 04/04/22 WHO suspends U.N. supply of Bharat Biotech's Covaxin, Reuters reports 01/19/22 India panel recommends market approval for Covaxin, says Press Trust of India OCGN Ocugen $2.23 / -0.01 (-0.45%) 04/12/22 What You Missed On Wall Street This Morning 04/04/22 What You Missed On Wall Street On Monday 04/04/22 What You Missed On Wall Street This Morning 03/04/22 What You Missed On Wall Street On Friday 06/07/22 Ocugen Inc OCGN Ocugen $2.23 / -0.01 (-0.45%) 03/25/22 Largest borrow rate increases among liquid names 02/22/22 Unusually active option classes on open February 22nd 02/07/22 Largest borrow rate increases among liquid names 01/26/22 Largest borrow rate increases among liquid names
Recommendations	Nvidia price target lowered to $280 from $350 at UBS » 06:37 05/23/22 05/23 06:37 05/23/22 06:37 NVDA Nvidia $167.18 / -3.95 (-2.31%) UBS analyst Timothy… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options NVDA Nvidia $167.18 / -3.95 (-2.31%) 05/10/22 NetApp teams with Nvidia to accelerate HPC/AI supercomputing infrastructure 05/06/22 Nvidia pays $5.5M to settle SEC charges over crypto disclosures 04/14/22 Worldwide semiconductor revenue grew 26% in 2021, Gartner says 04/04/22 MicroVision appoints Jeffrey Herbst to board of directors NVDA Nvidia $167.18 / -3.95 (-2.31%) 05/20/22 Wells Fargo Nvidia price target lowered to $250 from $370 at Wells Fargo 05/20/22 Daiwa Daiwa sees six month 'danger zone' for semiconductor stocks 05/19/22 Wedbush Nvidia price target lowered to $190 from $300 at Wedbush 05/19/22 Oppenheimer Nvidia price target lowered to $300 from $350 at Oppenheimer NVDA Nvidia $167.18 / -3.95 (-2.31%) 02/16/22 Nvidia sees Q1 revenue $8.1B +/- 2%, consensus $7.29B 02/16/22 Nvidia reports Q4 EPS $1.32, consensus $1.22 02/16/22 Notable companies reporting after market close NVDA Nvidia $167.18 / -3.95 (-2.31%) 04/23/22 Nvidia could be big tech's next casualty, Barron's says 03/23/22 Nvidia 'interested' in exploring Intel as foundry, Reuters reports 03/23/22 Nvidia CEO says foundry talks with Intel 'would take long time,' Bloomberg says 03/23/22 Nvidia CEO says interested in exploring Intel as foundry, Reuters reports NVDA Nvidia $167.18 / -3.95 (-2.31%) 05/20/22 Here's What You Missed in Crypto This Week 05/13/22 Here's What You Missed in Crypto This Week 05/06/22 Here's What You Missed in Crypto This Week 05/03/22 What You Missed On Wall Street On Tuesday 05/25/22 Nvidia - NVDA 06/02/22 NVIDIA Corp. NVDA Nvidia $167.18 / -3.95 (-2.31%) 04/14/22 Notable open interest changes for April 14th 04/13/22 Notable open interest changes for April 13th 04/07/22 Notable open interest changes for April 7th 03/25/22 Notable open interest changes for March 25th

Initiation	Eli Lilly initiated with an Outperform at SVB Leerink » 06:36 05/23/22 05/23 06:36 05/23/22 06:36 LLY Eli Lilly $298.98 / +12.43 (+4.34%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LLY Eli Lilly $298.98 / +12.43 (+4.34%) 05/20/22 Eli Lilly, Incyte: EMA's CHMP issues positive opinion for OLUMIANT 05/19/22 Eli Lilly's selpercatinib granted FDA orphan designation 05/19/22 180 Degree Capital announces closing, receipt of $12.3M in cash 05/13/22 FDA approves Eli Lilly's Mounjaro injection for treatment of type 2 diabetes LLY Eli Lilly $298.98 / +12.43 (+4.34%) 05/02/22 Wells Fargo AbbVie price target raised to $200 from $165 at Wells Fargo 05/02/22 Mizuho Eli Lilly price target raised to $356 from $315 at Mizuho 04/29/22 Morgan Stanley Eli Lilly price target raised to $369 from $364 at Morgan Stanley 04/29/22 Wells Fargo Eli Lilly price target raised to $305 from $280 at Wells Fargo LLY Eli Lilly $298.98 / +12.43 (+4.34%) 04/28/22 Eli Lilly cuts FY22 EPS view to $8.15-$8.30 from $8.50-$8.65, consensus $8.19 04/28/22 Eli Lilly reports Q1 EPS $2.62, consensus $2.14 03/24/22 Erasca reports Q4 EPS ($1.85), consensus (34c) 02/03/22 Eli Lilly backs FY22 EPS view $8.50-$8.65, consensus $7.54 LLY Eli Lilly $298.98 / +12.43 (+4.34%) 03/15/22 Eli Lilly suspends exports of some medicines to Russia, Bloomberg reports 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports 02/24/22 Drugmakers criticize Medicare proposal on Biogen's Alzheimer's drug, WSJ says 02/10/22 FDA expresses concerns about quality of China-developed drugs, WSJ reports LLY Eli Lilly $298.98 / +12.43 (+4.34%) 04/28/22 What You Missed On Wall Street On Thursday 04/28/22 What You Missed On Wall Street This Morning 04/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/15/22 What You Missed On Wall Street On Tuesday 06/03/22 2022 ASCO Annual Meeting 08/04/22 Eli Lilly - LLY 05/31/22 Eli Lilly LLY Eli Lilly $298.98 / +12.43 (+4.34%) 02/18/22 Eli Lilly put volume heavy and directionally bearish 12/15/21 Early notable gainers among liquid option names on December 15th
Downgrade	Sumitomo Pharma downgraded to Neutral from Buy at Citi » 06:36 05/23/22 05/23 06:36 05/23/22 06:36 DNPUF Sumitomo Pharma $9.69 / + (+0.00%) Citi analyst Hidemaru… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research DNPUF Sumitomo Pharma $9.69 / + (+0.00%) 08/16/21 Jefferies Sumitomo Dainippon upgraded to Buy from Hold at Jefferies 06/14/21 Jefferies Sumitomo Dainippon downgraded to Hold from Buy at Jefferies
Periodicals	Musk's planned takeover of Twitter creates 'chaos tax,' WSJ reports » 06:34 05/23/22 05/23 06:34 05/23/22 06:34 TWTR Twitter $38.28 / +1 (+2.68%) Within 24-hours,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options TWTR Twitter $38.28 / +1 (+2.68%) 05/20/22 Elon Musk: We will never surrender/settle an unjust case against us 05/20/22 Musk denies he sexually harassed flight attendant on private jet 05/19/22 Twitter turns green after Bloomberg quotes management as saying deal progressing 05/19/22 Twitter introduces 'crisis misinformation policy' TWTR Twitter $38.28 / +1 (+2.68%) 05/17/22 Wedbush Tesla shares likely to be under pressure again Tuesday, says Wedbush 05/16/22 Wedbush Bot issue likely excuse for lower Twitter price or Musk walks away, says Wedbush 05/16/22 Citi Citi does not expect Twitter deal changes from spam review 05/13/22 Truist Twitter, Musk deal could get 'messy' if he tries to walk away, says Truist TWTR Twitter $38.28 / +1 (+2.68%) 04/28/22 Twitter withdrawing previously provided outlook given pending acquisition 04/28/22 Twitter reports Q1 EPS 90c, consensus 3c 02/10/22 Twitter expects FY22 revenue growth in low to mid 20's range 02/10/22 Twitter sees Q1 revenue $1.17B-$1.27B, consensus $1.26B TWTR Twitter $38.28 / +1 (+2.68%) 06:09 Today Thoma Bravo not readying rival bid for Twitter, NY Post reports 05/20/22 SpaceX paid $250,000 to settle harassment claim against Musk, Insider reports 05/19/22 Twitter execs say deal proceeding as planned, not 'on hold,' Bloomberg reports 05/19/22 Twitter execs say deal not 'on hold,' proceeding as planned, Bloomberg reports TWTR Twitter $38.28 / +1 (+2.68%) 05/19/22 What You Missed On Wall Street On Thursday 05/18/22 #SocialStocks: Musk and Twitter working to close $44B deal, despite noise 05/18/22 What You Missed On Wall Street This Morning 05/17/22 What You Missed On Wall Street On Tuesday 05/25/22 Twitter, Inc. TWTR Twitter $38.28 / +1 (+2.68%) 05/18/22 Notable open interest changes for May 18th 05/17/22 Notable open interest changes for May 17th 05/16/22 Notable open interest changes for May 16th 05/13/22 Notable open interest changes for May 13th
Periodicals	Electronic Arts reportedly looking to sell or merge, Kotaku reports » 06:34 05/23/22 05/23 06:34 05/23/22 06:34 EA Electronic Arts $130.77 / +0.725 (+0.56%) , CMCSA Comcast $41.99 / -0.04 (-0.10%) , DIS Disney $102.38 / -0.81 (-0.78%) , AAPL Apple $137.58 / +0.26 (+0.19%) , MSFT Microsoft $252.57 / -0.44 (-0.17%) , ATVI Activision Blizzard $77.40 / -0.345 (-0.44%) EA (EA) recently pursued… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options EA CMCSA DIS AAPL MSFT ATVI EA Electronic Arts $130.77 / +0.725 (+0.56%) 05/13/22 'LEGO Star Wars' was best-selling game in April in U.S., says NPD 05/13/22 U.S. video game spending fell 8% y/y in April, says NPD 05/12/22 EA says 'Dead Space' remake out January 27, 2023 05/10/22 Electronic Arts raises quarterly dividend to 19c from 17c per share CMCSA Comcast $41.99 / -0.04 (-0.10%) 05/14/22 Trian exits Comcast position, increases stake in Invesco 05/12/22 Marcien Jenckes named president of Comcast, Charter joint venture 05/09/22 Comcast announces additional efforts for Affordable Connectivity Program 05/09/22 Internet providers join President Biden's Affordable Connectivity Program DIS Disney $102.38 / -0.81 (-0.78%) 05/22/22 Fly Intel: Top five weekend stock stories 05/18/22 Genius Brands signs 20-year deal with Marvel Studies to license 'Stan Lee' 05/17/22 Disney, XFL reach exclusive, global multi-year broadcast agreement 05/15/22 Fly Intel: Top five weekend stock stories AAPL Apple $137.58 / +0.26 (+0.19%) 05/16/22 Berkshire Hathaway adds Citi, exits Wells Fargo in Q1 05/16/22 Soros Capital buys Suncor and Mosaic during Q1, exits Alphabet 05/11/22 Google Maps debuts new 'immersive view' for cities in Google Maps 05/10/22 Apple says iPod touch will be 'available while supplies last' MSFT Microsoft $252.57 / -0.44 (-0.17%) 05/19/22 CD Projekt says next-gen 'Witcher 3' version to release in 4Q22 05/19/22 National Research Corporation appoints Parul Bhandari to board 05/19/22 Itron expands collaboration with Microsoft on cloud solutions for energy 05/18/22 American Airlines to use Microsoft Azure as its preferred cloud platform ATVI Activision Blizzard $77.40 / -0.345 (-0.44%) 05/16/22 Berkshire Hathaway adds Citi, exits Wells Fargo in Q1 05/13/22 Soros buys Lucid, exits GM in Q1 05/13/22 'LEGO Star Wars' was best-selling game in April in U.S., says NPD 05/13/22 U.S. video game spending fell 8% y/y in April, says NPD EA CMCSA DIS AAPL MSFT ATVI EA Electronic Arts $130.77 / +0.725 (+0.56%) 05/17/22 Morgan Stanley Take-Two price target lowered to $195 from $215 at Morgan Stanley 05/11/22 Wells Fargo Electronic Arts price target lowered to $145 from $155 at Wells Fargo 05/11/22 Wedbush Electronic Arts price target lowered to $164 from $180 at Wedbush 05/11/22 Cowen Electronic Arts price target lowered to $158 from $180 at Cowen CMCSA Comcast $41.99 / -0.04 (-0.10%) 05/06/22 Truist Cable One price target lowered to $1,400 from $2,000 at Truist 04/29/22 Morgan Stanley Comcast price target lowered to $55 from $60 at Morgan Stanley 04/29/22 Needham Accolade price target lowered to $12 from $33 at Needham 04/29/22 Deutsche Bank Comcast price target lowered to $60 from $62 at Deutsche Bank DIS Disney $102.38 / -0.81 (-0.78%) 05:08 Today KGI Securities Disney initiated with an Outperform at KGI Securities 05/16/22 Stifel Trade Desk upgraded to Buy from Hold at Stifel 05/13/22 Barclays Disney price target lowered to $130 from $168 at Barclays 05/12/22 RBC Capital Disney price target lowered to $176 from $210 at RBC Capital AAPL Apple $137.58 / +0.26 (+0.19%) 05/20/22 Wedbush Apple a compelling name to own, ride out market storm, says Wedbush 05/19/22 BofA BofA raises iPhone estimates, trims Apple price target to $200 05/11/22 JMP Securities Jamf Holding price target lowered to $39 from $59 at JMP Securities 05/04/22 Benchmark Cirrus Logic price target lowered to $95 from $100 at Benchmark MSFT Microsoft $252.57 / -0.44 (-0.17%) 05/19/22 RBC Capital Microsoft investor meetings indicate no change to macro/demand, says RBC Capital 05/13/22 Tigress Financial Microsoft pullback 'major buying opportunity,' says Tigress Financial 05/06/22 Benchmark Playstudios could still be target as industry consolidates, says Benchmark 04/29/22 OTR Global Okta view downgraded to Negative from Mixed at OTR Global ATVI Activision Blizzard $77.40 / -0.345 (-0.44%) 05/06/22 Benchmark Playstudios could still be target as industry consolidates, says Benchmark 04/25/22 Benchmark Activision results for Blizzard 'somewhat shocking,' says Benchmark 04/19/22 Goldman Sachs Activision Blizzard assumed with Not Rated at Goldman Sachs 02/28/22 Benchmark Playstudios could be target as game industry consolidates, says Benchmark EA CMCSA DIS AAPL MSFT ATVI EA Electronic Arts $130.77 / +0.725 (+0.56%) 05/10/22 Electronic Arts sees Q1 EPS 76c-85c, consensus 83c 05/10/22 Electronic Arts sees FY23 EPS $2.79-$2.87, consensus $7.43 05/10/22 Electronic Arts reports Q4 EPS 80c, consensus $1.43 05/10/22 Notable companies reporting after market close CMCSA Comcast $41.99 / -0.04 (-0.10%) 04/28/22 Comcast reports Q1 adjusted EPS 86c, consensus 80c 04/27/22 Notable companies reporting before tomorrow's open 04/27/22 Notable companies reporting before tomorrow's open 01/27/22 Comcast reports Q4 adjusted EPS 77c, consensus 73c DIS Disney $102.38 / -0.81 (-0.78%) 05/11/22 Disney reports Q2 EPS ex-items $1.08, consensus $1.17 05/11/22 Notable companies reporting after market close 02/09/22 Disney reports Q1 EPS ex-items $1.06, consensus 57c 02/09/22 Notable companies reporting after market close AAPL Apple $137.58 / +0.26 (+0.19%) 04/28/22 Apple says y/y Q3 revenue growth to be impacted by COVID 04/28/22 Apple reports Q2 EPS $1.52, consensus $1.43 04/28/22 Notable companies reporting after market close 02/27/22 Berkshire operating earnings surge, Buffett repurchases record $27B in stock MSFT Microsoft $252.57 / -0.44 (-0.17%) 04/26/22 Microsoft sees Q4 productivity and business processes revenue $16.65B-$16.9B 04/26/22 Microsoft reports Q3 EPS $2.22 consensus $2.18 04/26/22 Notable companies reporting after market close 01/25/22 Microsoft reports Q2 EPS $2.48, consensus $2.31 ATVI Activision Blizzard $77.40 / -0.345 (-0.44%) 04/25/22 Activision Blizzard reports Q1 EPS 64c, consensus 70c 02/03/22 Activision Blizzard reports Q4 adjusted EPS $1.01, consensus $1.31 02/03/22 Notable companies reporting after market close EA CMCSA DIS AAPL MSFT ATVI EA Electronic Arts $130.77 / +0.725 (+0.56%) 04/25/22 BioWare contractors preparing union vote, Kotaku reports 04/14/22 'Elden Ring' top-selling game in Europe in March, Gamesindustry.biz says 04/01/22 ESA cancels digital E3 2022 event, IGN reports 03/15/22 Electronic Arts tells IGN it won't host EA Play Live this year CMCSA Comcast $41.99 / -0.04 (-0.10%) 04/19/22 Users report issues with Hulu, DownDetector says 04/01/22 WWE producing two traditional tv shows about wrestling, WSJ reports 03/30/22 Hulu loses Paramount, MGM films as EPIX deal ends, The Streamable says 03/11/22 NBC's Peacock near deal on MLB games streaming, WSJ reports DIS Disney $102.38 / -0.81 (-0.78%) 05/02/22 Disney's corporate affairs head Geoff Morrell exits, WSJ reports 05/01/22 Disney's clash with Florida has CEOs on alert, WSJ reports 04/28/22 ESPN anchor Steele sues network, alleges violation of free-speech, WSJ reports 04/22/22 Florida Governor signs bill to eliminate Disney's special tax district, WSJ says AAPL Apple $137.58 / +0.26 (+0.19%) 06:06 Today Apple to release new HomePod in 4Q22 or 1Q23, MacRumors reports 05/22/22 Apple looking to boost production outside China, WSJ reports 05/19/22 Apple previewed mixed-reality headset to board, Bloomberg reports 05/17/22 Apple delays plan to have employees in office three days a week, Bloomberg says MSFT Microsoft $252.57 / -0.44 (-0.17%) 05/19/22 Microsoft president says Activision Blizzard deal proceeding quickly, VGC says 05/19/22 Xbox Series S outsold PlayStation 5 in Japan last week, Famitsu reports 05/18/22 Parent sues Blizzard over non-refundable 'Hearthstone' cards, Polygon reports 05/16/22 Microsoft CEO tells staff pay hikes are coming, CNBC reports ATVI Activision Blizzard $77.40 / -0.345 (-0.44%) 05/19/22 Microsoft president says Activision Blizzard deal proceeding quickly, VGC says 05/18/22 Parent sues Blizzard over non-refundable 'Hearthstone' cards, Polygon reports 05/04/22 Activision CEO sued by NYC over allegedly rushing Microsoft deal, Axios says 05/01/22 Buffett reveals big investments at Berkshire meeting, Reuters reports EA CMCSA DIS AAPL MSFT ATVI EA Electronic Arts $130.77 / +0.725 (+0.56%) 05/17/22 What You Missed This Week in Video Games 05/11/22 What You Missed On Wall Street On Wednesday 05/11/22 What You Missed On Wall Street This Morning 05/11/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations CMCSA Comcast $41.99 / -0.04 (-0.10%) 05/22/22 Box Office Battle: 'Doctor Strange 2' wins weekend with another $31.6M 05/15/22 Box Office Battle: 'Doctor Strange 2' wins weekend with another $61M 05/08/22 Box Office Battle: 'Doctor Strange 2' scores one of the top launches of all time 05/01/22 Box Office Battle: 'The Bad Guys' stays number 1 with $16.1M outing DIS Disney $102.38 / -0.81 (-0.78%) 05/22/22 Box Office Battle: 'Doctor Strange 2' wins weekend with another $31.6M 05/16/22 Wall Street calls out this stock as a winner from Netflix adding ads 05/16/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/15/22 Box Office Battle: 'Doctor Strange 2' wins weekend with another $61M AAPL Apple $137.58 / +0.26 (+0.19%) 05/19/22 What You Missed On Wall Street On Thursday 05/17/22 What You Missed On Wall Street On Tuesday 05/10/22 What You Missed On Wall Street On Tuesday 05/09/22 Fly Insider: Kennametal, Apple among notable insider trades this week MSFT Microsoft $252.57 / -0.44 (-0.17%) 05/19/22 What You Missed On Wall Street On Thursday 05/17/22 What You Missed This Week in Video Games 05/12/22 What You Missed On Wall Street This Morning 05/10/22 What You Missed This Week in Video Games ATVI Activision Blizzard $77.40 / -0.345 (-0.44%) 05/19/22 What You Missed On Wall Street On Thursday 05/17/22 What You Missed This Week in Video Games 05/10/22 What You Missed This Week in Video Games 05/03/22 What You Missed This Week in Video Games 00:00 Today 50th Annual Global Technology, Media & Communications Conference 06/01/22 50th Annual Technology, Media & Telecom Conference 06/14/22 Microsoft - MSFT 08/02/22 Electronic Arts - EA 06/01/22 Comcast Corporation 06/06/22 Microsoft 06/21/22 Activision Blizzard, Inc. EA CMCSA DIS AAPL MSFT ATVI EA Electronic Arts $130.77 / +0.725 (+0.56%) 05/11/22 Early notable gainers among liquid option names on May 11th 02/22/22 Electronic Arts call volume above normal and directionally bullish 02/01/22 Electronic Arts options imply 5.5% move in share price post-earnings 01/20/22 Electronic Arts call volume above normal and directionally bullish CMCSA Comcast $41.99 / -0.04 (-0.10%) 05/09/22 Comcast call volume above normal and directionally bullish 04/25/22 Comcast put volume heavy and directionally bearish 04/21/22 Comcast put volume heavy and directionally bearish 02/18/22 Comcast put volume heavy and directionally bearish DIS Disney $102.38 / -0.81 (-0.78%) 05/11/22 Disney options imply 8.5% move in share price post-earnings 05/09/22 Unusually active option classes on open May 9th 04/20/22 Unusually active option classes on open April 20th 02/10/22 Early notable gainers among liquid option names on February 10th AAPL Apple $137.58 / +0.26 (+0.19%) 05/20/22 Notable open interest changes for May 20th 05/19/22 Notable open interest changes for May 19th 05/18/22 Notable open interest changes for May 18th 05/17/22 Notable open interest changes for May 17th MSFT Microsoft $252.57 / -0.44 (-0.17%) 05/02/22 Microsoft put buyer realizes 57% same-day gains 04/27/22 Early notable gainers among liquid option names on April 27th 04/27/22 Notable open interest changes for April 27th 04/26/22 Microsoft call buyer realizes 19% same-day gains ATVI Activision Blizzard $77.40 / -0.345 (-0.44%) 05/02/22 Unusually active option classes on open May 2nd 04/25/22 Unusually active option classes on open April 25th 04/18/22 Activision Blizzard call volume above normal and directionally bullish 02/04/22 Notable open interest changes for February 4th
Conference/Events	Syros Pharmaceuticals management to meet virtually with Oppenheimer » 06:34 05/23/22 05/23 06:34 05/23/22 06:34 SYRS Syros Pharmaceuticals / + Virtual Meeting to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events SYRS Syros Pharmaceuticals / + 04/08/22 Syros Pharmaceuticals presents preclinical data on CDK12 inhibitor program 02/02/22 Syros Pharmaceuticals gets FDA orphan drug designation for Tamibarotene in MDS 02/01/22 Syros Pharmaceuticals receives FDA orphan drug designation for tamibarotene 01/10/22 Syros Pharmaceuticals updates on clinical development program SYRS Syros Pharmaceuticals / + 05/17/22 H.C. Wainwright Syros Pharmaceuticals price target lowered to $10 from $15 at H.C. Wainwright 05/16/22 Alliance Global Partners Syros Pharmaceuticals price target lowered to $10 at Alliance Global Partners 03/16/22 Roth Capital Roth 'struggles to understand' why Syros trades at $1.15 with 3 readouts ahead 01/10/22 Piper Sandler Syros Pharmaceuticals price target lowered to $10 from $18 at Piper Sandler SYRS Syros Pharmaceuticals / + 05/16/22 Syros Pharmaceuticals reports Q1 EPS (40c), consensus (47c) 03/15/22 Syros Pharmaceuticals reports Q4 EPS (38c), consensus (47c) 05/24/22 Syros Pharmaceuticals 06/01/22 Syros Pharmaceuticals, Inc.

Initiation	Halozyme initiated with an Outperform at SVB Leerink » 06:34 05/23/22 05/23 06:34 05/23/22 06:34 HALO Halozyme $44.34 / +0.47 (+1.07%) , ATRS Antares Pharma $5.59 / -0.005 (-0.09%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly HALO ATRS HALO Halozyme $44.34 / +0.47 (+1.07%) 05/12/22 Halozyme's acquisition of Antares Pharma completes HSR waiting period 04/26/22 Halozyme announces tender offer to acquire outstanding shares of Antares Pharma 04/13/22 Halozyme to acquire Antares Pharma for $5.60 per share 03/24/22 Halozyme, Chugai enter global collaboration, license pact for ENHANZE technology ATRS Antares Pharma $5.59 / -0.005 (-0.09%) 05/17/22 Talaris Therapeutics annouces changes to board of directors 05/12/22 Halozyme's acquisition of Antares Pharma completes HSR waiting period 04/26/22 Halozyme announces tender offer to acquire outstanding shares of Antares Pharma 04/13/22 Halozyme to acquire Antares Pharma for $5.60 per share HALO ATRS HALO Halozyme $44.34 / +0.47 (+1.07%) 04/14/22 Truist Antares Pharma downgraded to Hold from Buy at Truist 04/14/22 Raymond James Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James 04/13/22 Piper Sandler Piper says Antares' auto-injector platform 'clearly complementary' for Halozyme 03/24/22 Benchmark Halozyme 'off to a good start' to 2022 with Chugai deal, says Benchmark ATRS Antares Pharma $5.59 / -0.005 (-0.09%) 04/14/22 Truist Antares Pharma downgraded to Hold from Buy at Truist 04/14/22 Ladenburg Antares Pharma downgraded to Neutral from Buy at Ladenburg 04/14/22 Raymond James Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James 04/14/22 Piper Sandler Antares Pharma downgraded to Neutral from Overweight at Piper Sandler HALO ATRS HALO Halozyme $44.34 / +0.47 (+1.07%) 05/10/22 Halozyme reaffirms FY22 non-GAAP EPS view $2.05-$2.20, consensus $2.23 05/10/22 Halozyme reports Q1 non-GAAP EPS 47c, consensus 49c 02/22/22 Halozyme sees 2022 non-GAAP EPS $2.05-$2.20, consensus $2.18 02/22/22 Halozyme reports Q4 non-GAAP EPS 42c, consensus 41c ATRS Antares Pharma $5.59 / -0.005 (-0.09%) 03/03/22 Antares Pharma sees 2022 revenue $200M-$220M, consensus $211.41M 03/03/22 Antares Pharma reports Q4 adjusted EPS 2c, consensus 1c HALO ATRS HALO Halozyme $44.34 / +0.47 (+1.07%) 04/13/22 What You Missed On Wall Street On Wednesday 04/13/22 What You Missed On Wall Street This Morning 12/09/21 Fly Intel: After-Hours Movers ATRS Antares Pharma $5.59 / -0.005 (-0.09%) 04/13/22 What You Missed On Wall Street On Wednesday 04/13/22 What You Missed On Wall Street This Morning
Downgrade	Realty Income downgraded to Peer Perform from Outperform at Wolfe Research » 06:33 05/23/22 05/23 06:33 05/23/22 06:33 O Realty Income $68.00 / +0.84 (+1.25%) Wolfe Research analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly O Realty Income $68.00 / +0.84 (+1.25%) 03/15/22 Realty Income raises quarterly dividend by 0.2% to 24.7c per share 02/15/22 Realty Income to acquire Encore Boston Harbor via partnership with Wynn Resorts 02/15/22 Wynn Resorts to sell real estate of Encore Boston Harbor for $1.70B 12/15/21 Realty Income raises monthly divided to 24.65c per share from 24.6c O Realty Income $68.00 / +0.84 (+1.25%) 03/15/22 Wolfe Research Realty Income upgraded to Outperform from Peer Perform at Wolfe Research 01/20/22 Mizuho Realty Income price target lowered to $76 from $82 at Mizuho 12/15/21 Scotiabank Realty Income downgraded to Sector Perform from Outperform at Scotiabank 12/15/21 Scotiabank Realty Income downgraded to Sector Perform from Outperform at Scotiabank O Realty Income $68.00 / +0.84 (+1.25%) 05/04/22 Realty Income still sees 2022 AFFO $3.84-$3.97, consensus $3.94 05/04/22 Realty Income reports Q1 adjusted FFO 98c, consensus 97c 02/22/22 Realty Income sees 2022 AFFO $3.84-$3.97, consensus $3.93 02/22/22 Realty Income reports Q4 AFFO 94c, consensus 93c 01 Jul O Realty Income $68.00 / +0.84 (+1.25%) 02/18/22 Bet On It: DraftKings cites unstable stock market for post-earnings dip 02/16/22 What You Missed On Wall Street This Morning
Downgrade	JBG Smith downgraded to Peer Perform from Outperform at Wolfe Research » 06:33 05/23/22 05/23 06:33 05/23/22 06:33 JBGS JBG Smith Properties $24.97 / +0.045 (+0.18%) Wolfe Research analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research JBGS JBG Smith Properties $24.97 / +0.045 (+0.18%) 02/14/22 JBG Smith Properties forms office portfolio JV with Fortress Investment JBGS JBG Smith Properties $24.97 / +0.045 (+0.18%) 03/03/22 Evercore ISI Evercore ISI shakes up Office REIT ratings with one upgrade, two downgrades 07/12/21 BMO Capital JBG Smith Properties initiated with an Outperform at BMO Capital
Hot Stocks	ImmunoGen's BLA for mirvetuximab soravtansine in ovarian cancer accepted by FDA » 06:32 05/23/22 05/23 06:32 05/23/22 06:32 IMGN ImmunoGen $3.58 / +0.055 (+1.56%) ImmunoGen announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events IMGN ImmunoGen $3.58 / +0.055 (+1.56%) 03/29/22 ImmunoGen submits BLA to FDA for mirvetuximab soravtansine 03/20/22 ImmunoGen presents full results from pivotal SORAYA trial 02/16/22 eFfector Therapeutics appoints Kristen Harrington-Smith to boardImmunoGen 02/15/22 ImmunoGen announces global licensing agreement with Eli Lilly IMGN ImmunoGen $3.58 / +0.055 (+1.56%) 03/21/22 RBC Capital ImmunoGen downgraded to Sector Perform from Outperform at RBC Capital 02/10/22 BMO Capital ImmunoGen initiated with an Outperform at BMO Capital 01/03/22 Guggenheim ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim 12/01/21 Jefferies ImmunoGen upgraded to Buy at Jefferies after 'best-case data' in PROC IMGN ImmunoGen $3.58 / +0.055 (+1.56%) 05/06/22 ImmunoGen still sees 2022 revenue $75M-$85M, consensus $84.98M 05/06/22 ImmunoGen reports Q1 EPS (10c), consensus (21c) 02/25/22 ImmunoGen sees FY22 revenue $75M-$85M, consensus $63.61M 02/25/22 ImmunoGen reports Q4 EPS (17c), consensus ($1.71) 02 Dec IMGN ImmunoGen $3.58 / +0.055 (+1.56%) 03/21/22 What You Missed On Wall Street On Monday 03/21/22 What You Missed On Wall Street This Morning 03/21/22 Fly Intel: Pre-market Movers 12/01/21 Wall Street in Fives - Must Read Lists at Midday 06/03/22 2022 ASCO Annual Meeting 06/15/22 ImmunoGen, Inc.
Initiation	Johnson & Johnson assumed with an Outperform at SVB Leerink » 06:31 05/23/22 05/23 06:31 05/23/22 06:31 JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) SVB Leerink analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 05/18/22 Tesla ineligible for S&P 500 ESG Index inclusion, S&P announces 05/11/22 J&J appoints Thibaut Mongon as CEO Designate of new consumer health company 05/05/22 FDA limits authorized use of J&J's COVID vaccine 05/02/22 FDA announces tentative advisory committee meetings on COVID-19 vaccines JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 05/17/22 BofA Teva upgraded to Neutral at BofA on potential opioid deal upside 05/17/22 Citi Johnson & Johnson price target lowered to $205 from $210 at Citi 04/29/22 Chardan Emergent BioSolutions price target lowered to $65 from $75 at Chardan 04/20/22 Credit Suisse Johnson & Johnson price target raised to $205 from $200 at Credit Suisse JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 04/19/22 Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60 04/19/22 Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61 04/18/22 Notable companies reporting before tomorrow's open 04/18/22 Notable companies reporting before tomorrow's open JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 05/10/22 Emergent plant's quality problems led to 400M discarded vaccines, WSJ reports 05/05/22 J&J sues SaveOnSP over use of drug cost assistance program, WSJ reports 04/27/22 J&J files suit against HIV-drug counterfeit distributors, WSJ reports 03/30/22 DOJ probes network accused of selling counterfeit HIV drugs, WSJ reports JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 05/06/22 What You Missed On Wall Street On Friday 05/06/22 What You Missed On Wall Street This Morning 04/27/22 What You Missed On Wall Street On Wednesday 04/27/22 What You Missed On Wall Street This Morning 06/02/22 38th Annual Strategic Decisions Conference 09/07/22 2022 Wells Fargo Healthcare Conference 07/19/22 Johnson & Johnson - JNJ JNJ Johnson & Johnson $175.81 / +2.97 (+1.72%) 04/19/22 Unusually active option classes on open April 19th 01/25/22 Unusually active option classes on open January 25th 12/17/21 Unusually active option classes on open December 17th

Events

Earnings calls, analyst events, roadshows and more

XPEV
Today at 08:00

XPeng - XPEV Conference Calls
NIU
Today at 08:00

Niu Technologies - NIU Conference Calls
CAAS
Today at 08:00

China Automotive - CAAS Conference Calls
CSTE
Today at 08:00

Caesarstone Firm Sponsored Meetings

Virtual Meeting
JPM
Today at 08:00

JPMorgan Firm Sponsored Meetings

Virtual Meeting
Today at 08:30

Chicago Fed National Activity Index--3 Month Moving Average: April 2022 Government Event
Today at 08:30

Chicago Fed National Activity Index: April 2022 Government Event
RSLS
Today at 08:30

ReShape Lifesciences - RSLS Conference Calls
AVPT
Today at 09:00

AvePoint Firm Sponsored Meetings

Virtual Meeting
GILT
Today at 09:30

Gilat Satellite - GILT Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Deutsche Bank sees 2022 guidance misses from these auto companies

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access